Sociodemographic disparities, such as low income and lack of health insurance, contribute to reduced CRC screening at age 45 years.

Ambulatory acute kidney injury is common among individuals with cirrhosis and is associated with a high 90-day mortality.

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis.

Experienced weight stigma improves from pre- to post-metabolic bariatric surgery, according to a recent study.

Early-life factors are associated with body mass index trajectories in children, with risk for obesity detectable at age 3.5 years.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

More than one-third of patients with SSc screened positive for self-reported depression, with GI involvement identified as the most significant predictor.

Patients with eosinophilic esophagitis in the US have high health care resource utilization costs, according to a retrospective national claims study.

Among patients with concomitant primary sclerosing cholangitis and IBD, liver transplant is linked to a lower risk for colorectal neoplasia.